Volume 7, Issue 2 (2026)                   3 2026, 7(2): 101-106 | Back to browse issues page
Request Type:
Original Research |

Print XML PDF HTML


History

How to cite this article
Naser H, Al-Semaiil F, Mohammed M, Abbas B. Isolation and Identification of Proteus mirabilis from Clinical Samples Using the VITEK-2 Automated System. 3 2026; 7 (2) :101-106
URL: http://jccs.daneshafarand.org/article-8-87254-en.html
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Rights and permissions
1- Department of Pathological Analyses, Faculty of Science, Al-Kunooze University, Basra, Iraq
2- Department of Science, College of Education Open (Al-Dujail Study Branch), Al-Dujail, Iraq
3- Department of Pathological Analysis, Faculty of Health and Medical Techniques, Al-Kunooze University, Basra, Iraq, Department of Pathological Analysis, Faculty of Health and Medical Techniques, Al-Kunooze University, Street/Al-Zaytoon, Basra, Iraq. Postal Code: 610001 (basilabbas63@gmail.com)
Abstract   (79 Views)
Aims: This study aimed to systematically characterize the phenotypic profiles of clinical Proteus mirabilis isolates identified using the VITEK 2 GN card and to determine the consistency and intraspecies variability of the biochemical reactions underlying their identification.
Materials & Methods: This descriptive observational study was conducted in 2025. Twenty-three clinical Gram-negative isolates obtained from over 150 urine samples were identified using the VITEK 2 GN card. Identification probability, bionumbers, analysis time, and the binary results of 47 biochemical reactions were obtained from the instrument reports. The isolates identified as Proteus mirabilis were further evaluated based on their individual biochemical profiles to determine the consistency and variability of the detected reactions.
Findings: VITEK 2 identified 18/23 isolates (78.3%) with probabilities ≥90%, whereas 5/23 (21.7%) were reported as “Unidentified Organism.” Proteus mirabilis was the most frequent identification (9/23; 39.1%); eight isolates showed 99% probability, and one showed 96%, with a mean analysis time of 3.84 hours. All Proteus mirabilis isolates were positive for H₂S, D-glucose, D-trehalose, phosphatase, coumarate, and O/129 resistance. ODC was positive in 8/9 (88.9%), whereas LDC was negative in all isolates. Urease and γ-glutamyl transferase were positive in 7/9 (77.8%) and 8/9 (88.9%) of the isolates, respectively, whereas tyrosine arylamidase and citrate utilization showed greater variability. Nine distinct bionumbers indicated limited biochemical variation among the isolates.
Conclusion: The VITEK 2 GN card provides high-confidence identification of Proteus mirabilis and demonstrates a consistent biochemical profile across the isolates.
 
Keywords:
|   |   Full-Text (HTML)  (6 Views)  

References
1. Palusiak A. Proteus mirabilis and Klebsiella pneumoniae as pathogens capable of causing co-infections and exhibiting similarities in their virulence factors. Front Cell Infect Microbiol. 2022;12:991657. [Link] [DOI:10.3389/fcimb.2022.991657]
2. Muhsal LK, Theis L, Overmann J, Hamprecht A. Proteus spp.-taxonomy, clinical significance, and antibiotic resistance of a highly versatile pathogen. Clin Microbiol Rev. 2025;38(4):e0018124. [Link] [DOI:10.1128/cmr.00181-24]
3. Chakkour M, Hammoud Z, Farhat S, El Roz A, Ezzeddine Z, Ghssein G. Overview of Proteus mirabilis pathogenicity and virulence. Insights into the role of metals. Front Microbiol. 2024;15:1383618. [Link] [DOI:10.3389/fmicb.2024.1383618]
4. Gmiter D, Kaca W. Into the understanding the multicellular lifestyle of Proteus mirabilis on solid surfaces. Front Cell Infect Microbiol. 2022;12:864305. [Link] [DOI:10.3389/fcimb.2022.864305]
5. Veisi M, Hosseini-Nave H, Tadjrobehkar O. Biofilm formation ability and swarming motility are associated with some virulence genes in Proteus mirabilis. BMC Microbiol. 2025;25(1):388. [Link] [DOI:10.1186/s12866-025-04090-5]
6. Nissanka MC, Dilhari A, Munasinghe JA, Priyadarshana G, Bandara K, Munaweera I, et al. Decoding Proteus mirabilis biofilms: Expression of selected virulence genes and association with antibiotic resistance. BMC Microbiol. 2025;25(1):481. [Link] [DOI:10.1186/s12866-025-04212-z]
7. Fitzgerald MJ, Pearson MM, Mobley HLT. Proteus mirabilis UreR coordinates cellular functions required for urease activity. J Bacteriol. 2024;206(4):e0003124. [Link] [DOI:10.1128/jb.00031-24]
8. Sannathimmappa MB, Nambiar V, Al-Maqbali S. Proteus mirabilis infections in a secondary-care hospital in Oman: Epidemiology, antimicrobial resistance, and predictors of in-hospital mortality. Egypt J Intern Med. 2026;38:81. [Link] [DOI:10.1186/s43162-026-00657-4]
9. Hameed TR, Al-Rawi DF, Ali LH. Antibiotic susceptibility testing of Proteus mirabilis isolates from selected hospitals in Anbar governorate, Iraq. Babcock Univ Med J. 2025;8(2):304-9. [Link] [DOI:10.38029/babcockuniv.med.j..v8i2.1051]
10. Li Y, Yin M, Fang C, Fu Y, Dai X, Zeng W, et al. Genetic analysis of resistance and virulence characteristics of clinical multidrug-resistant Proteus mirabilis isolates. Front Cell Infect Microbiol. 2023;13:1229194. [Link] [DOI:10.3389/fcimb.2023.1229194]
11. ElTaweel M, Said HS, Barwa R. Emergence of extensive drug resistance and high prevalence of multidrug resistance among clinical Proteus mirabilis isolates in Egypt. Ann Clin Microbiol Antimicrob. 2024;23(1):46. [Link] [DOI:10.1186/s12941-024-00705-3]
12. Kotb DN, Zaki S, Abdelrahim SS. Assessment of genetic determinants of virulence and fluoroquinolone resistance in Proteus mirabilis isolates from urinary tract infections in Egypt. BMC Infect Dis. 2026;26(1):1271. [Link] [DOI:10.1186/s12879-026-13838-x]
13. Ibrahim MA, Faisal RM. Molecular characterization of antibiotic resistance and virulence genes on plasmids of Proteus mirabilis isolated from urine samples of hospitals in Mosul City, Iraq. J Appl Nat Sci. 2024;16(2):830-41. [Link] [DOI:10.31018/jans.v16i2.5526]
14. Qu X, Zhou J, Huang H, Wang W, Xiao Y, Tang B, et al. Genomic investigation of Proteus mirabilis isolates recovered from pig farms in Zhejiang Province, China. Front Microbiol. 2022;13:952982. [Link] [DOI:10.3389/fmicb.2022.952982]
15. Liu L, Dong Z, Ai S, Chen S, Dong M, Li Q, et al. Virulence-related factors and antimicrobial resistance in Proteus mirabilis isolated from domestic and stray dogs. Front Microbiol. 2023;14:1141418. [Link] [DOI:10.3389/fmicb.2023.1141418]
16. Yaikhan T, Sukpan P, Pakhawan J, Chusri S, Dechathai T, Suwannasin S, et al. Phylogenomic structure and resistance profiles of clinical Proteus mirabilis from a Thai hospital. Infect Genet Evol. 2026;143:105980. [Link] [DOI:10.1016/j.meegid.2026.105980]
17. Ahmad IF, Ali IA. Genetic study of IntI1 and IntI2 resistance genes and multidrug resistance of Proteus mirabilis isolated from clinical isolates from patients in Diyala province, Iraq. J Appl Nat Sci. 2024;16(4):1639-47. [Link] [DOI:10.31018/jans.v16i4.6000]
18. Al-Jubouri SIS, Al-Tamimi BJ. Molecular analysis of virulence genes LuxS, RsbA and MrpA in Proteus mirabilis isolated from different clinical samples. Thi-Qar Med J. 2024;27(1). [Link]
19. Shaaban M, Abd El-Rahman OA, Al-Qaidi B, Ashour HM. Antimicrobial and antibiofilm activities of Probiotic Lactobacilli on antibiotic-resistant Proteus mirabilis. Microorganisms. 2020;8(6):960. [Link] [DOI:10.3390/microorganisms8060960]
20. Filipiak A, Chrapek M, Literacka E, Wawszczak M, Głuszek S, Majchrzak M, et al. Pathogenic factors correlate with antimicrobial resistance among clinical Proteus mirabilis strains. Front Microbiol. 2020;11:579389. [Link] [DOI:10.3389/fmicb.2020.579389]